Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes.

Auger and Alpha emitters PARP inhibition PARP1 theranostic probes PARP1 tracers PET/SPECT imaging

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
06 Jul 2020
Historique:
received: 11 06 2020
revised: 29 06 2020
accepted: 03 07 2020
entrez: 10 7 2020
pubmed: 10 7 2020
medline: 10 7 2020
Statut: epublish

Résumé

The central paradigm of novel therapeutic approaches in cancer therapy is identifying and targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly-(ADP ribose) polymerase 1 (PARP1). Sensitivity to PARP inhibition in certain cancers such as gBRCA

Identifiants

pubmed: 32640708
pii: jcm9072130
doi: 10.3390/jcm9072130
pmc: PMC7408801
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

J Nucl Med. 2019 Apr;60(4):504-510
pubmed: 30389822
Bioconjug Chem. 2019 May 15;30(5):1331-1342
pubmed: 30973715
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Radiology. 2017 Feb;282(2):453-463
pubmed: 27841728
Nat Biomed Eng. 2020 Mar;4(3):272-285
pubmed: 32165735
Mol Cancer Ther. 2019 Jul;18(7):1195-1204
pubmed: 31072830
J Neurosurg. 2017 Jan;126(1):191-200
pubmed: 27035164
Nat Commun. 2020 Jan 30;11(1):594
pubmed: 32001707
Angew Chem Int Ed Engl. 2011 Feb 18;50(8):1922-5
pubmed: 21328671
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7441-E7449
pubmed: 28827325
Pharmacol Rev. 2013 Sep 24;65(4):1214-56
pubmed: 24064460
Bioconjug Chem. 2018 Nov 21;29(11):3776-3782
pubmed: 30354077
J Nucl Med. 2018 Aug;59(8):1225-1233
pubmed: 29572254
Clin Cancer Res. 2020 Jun 15;26(12):2871-2881
pubmed: 32066626
Clin Cancer Res. 2017 Dec 1;23(23):7165-7170
pubmed: 28751443
J Thorac Oncol. 2019 Oct;14(10):1743-1752
pubmed: 31195178
Nucl Med Biol. 2020 May - Jun;84-85:80-87
pubmed: 32135475
Clin Cancer Res. 2018 Sep 1;24(17):4066-4071
pubmed: 29650751
ChemMedChem. 2014 Jul;9(7):1368-73
pubmed: 24596307
Mol Imaging Biol. 2016 Jun;18(3):386-92
pubmed: 26493053
Theranostics. 2019 Aug 14;9(21):6224-6238
pubmed: 31534547
Br J Cancer. 2011 Oct 11;105(8):1114-22
pubmed: 21989215
J Pharm Pharmacol. 2008 Aug;60(8):951-8
pubmed: 18644188
J Nucl Med. 2020 Jun;61(6):850-856
pubmed: 31676730
Bioorg Chem. 2019 Mar;83:242-249
pubmed: 30390553
J Med Chem. 2018 May 10;61(9):4103-4114
pubmed: 29630818
Cancer Res. 2016 Aug 1;76(15):4516-24
pubmed: 27261505
Nanomedicine (Lond). 2012 Aug;7(8):1225-33
pubmed: 22931448
EJNMMI Res. 2015 Dec;5(1):123
pubmed: 26337803
Drugs. 2018 Dec;78(18):1939-1946
pubmed: 30506138
Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):94-101
pubmed: 27069769
Front Oncol. 2013 Aug 19;3:215
pubmed: 23967404
Oncotarget. 2018 Dec 14;9(98):37080-37096
pubmed: 30647846
J Clin Invest. 2018 May 1;128(5):2116-2126
pubmed: 29509546
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1065-1078
pubmed: 28058462
Nat Commun. 2018 Jan 12;9(1):176
pubmed: 29330466
J Labelled Comp Radiopharm. 2020 Jul;63(9):419-425
pubmed: 32391930
Front Oncol. 2019 Jan 22;8:670
pubmed: 30723695
Bioorg Med Chem. 2014 Mar 1;22(5):1700-7
pubmed: 24503274
Nucl Med Biol. 2018 Nov;66:26-31
pubmed: 30195072
Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621
pubmed: 28676700
Br J Cancer. 2014 Aug 12;111(4):651-9
pubmed: 25025963
Cancer Manag Res. 2019 May 10;11:4371-4390
pubmed: 31191001
Bioorg Med Chem Lett. 2017 Aug 1;27(15):3472-3476
pubmed: 28587822
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Nucl Med Biol. 2016 Dec;43(12):752-758
pubmed: 27689533
Semin Nucl Med. 2008 Sep;38(5):358-66
pubmed: 18662557
Neuro Oncol. 2020 Apr 29;:
pubmed: 32347934
Clin Cancer Res. 2015 Oct 1;21(19):4257-61
pubmed: 26187614
Chem Soc Rev. 2005 Feb;34(2):153-63
pubmed: 15672179
Nat Commun. 2018 May 18;9(1):1991
pubmed: 29777137
Clin Cancer Res. 2020 Jul 1;26(13):3110-3116
pubmed: 32245901
Nano Lett. 2011 Feb 9;11(2):814-9
pubmed: 21210706
J Med Chem. 2015 Nov 12;58(21):8683-93
pubmed: 26469301
Environ Mol Mutagen. 2017 Jun;58(5):235-263
pubmed: 28485537
Biomater Sci. 2017 May 2;5(5):1041-1050
pubmed: 28378865
Int J Gynecol Cancer. 2019 May 22;:
pubmed: 31118216
J Nucl Med. 2017 Jul;58(7):1025-1030
pubmed: 28473593
EJNMMI Res. 2018 Jul 4;8(1):59
pubmed: 29974335
Mol Imaging. 2017 Jan-Dec;16:1536012117723786
pubmed: 28856922

Auteurs

Ramya Ambur Sankaranarayanan (R)

Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany.

Susanne Kossatz (S)

Department of Nuclear Medicine, University Hospital Klinikum Rechts der Isar, Technical University Munich, 81675 Munich, Germany.
Central Institute for Translational Cancer Research (TranslaTUM), Technical University of Munich, 81675 Munich, Germany.
Department of Chemistry, Technical University of Munich, 85748 Munich, Germany.

Wolfgang Weber (W)

Department of Nuclear Medicine, University Hospital Klinikum Rechts der Isar, Technical University Munich, 81675 Munich, Germany.

Mohsen Beheshti (M)

Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany.
Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University, 5020 Salzburg, Austria.

Agnieszka Morgenroth (A)

Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany.

Felix M Mottaghy (FM)

Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany.
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), 6202 Maastricht, The Netherlands.

Classifications MeSH